| View |
|
BR-1293
|
Rituximab
|
Rituxikal (50)
|
500 mg/ 50 mL
|
Concentrate for Solution for Infusion
|
Prescription Drug (RX)
|
One 50 mL Type I borosilicate glass vial with chlorobutyl rubber stopper and alimunum flip-off foil seal a plastic tray (Box of 1's)
|
Antineoplastic
|
Sinergium Biotech S.A.
|
Argentina
|
|
Globo Asiatico Ent. Inc.
|
Globo Asiatico Ent. Inc.
|
Compliance MR
|
24 May 2019
|
24 May 2025
|
| View |
|
BR-1294
|
Rituximab
|
Rituxikal
|
100 mg/ 10 mL
|
Concentrate for Solution for Infusion
|
Prescription Drug (RX)
|
Two 10 mL Type I borosilicate glass vial with chlorobutyl rubber stopper and alimunum flip-off foil seal a plastic tray (Box of 2's)
|
Antineoplastic
|
Sinergium Biotech S.A.
|
Argentina
|
|
Globo Asiatico Ent. Inc.
|
Globo Asiatico Ent. Inc.
|
Compliance MR
|
24 May 2019
|
24 May 2025
|
| View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (RX)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (Rx)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type I Clear Glass Syringe Barrel, with 27g X 1/2" Needle, in a Pen delivery device (Box of l's, 2's, and 3's + Physician Sample). Single dose.
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1mL Type I clear prefilled glass syringe with 27 G 1/2 needle (Box of 1's, 2's and 3's). Single dose.
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
|
BR-1303
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 720
|
720 ELISA units/0.5 mL
|
Suspension for Injection (IM)
|
Prescription Drug (Rx)
|
Type I pre-filled glass syringe x 0.5 mL, with separate
needle, packed in a blister (Box of 1's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
|
GlaxoSmithKline Philippines, Inc.
|
|
Initial (Variation)
|
28 June 2024
|
28 June 2029
|
| View |
|
BR-1304
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 1440
|
1440 ELISA units/mL
|
Suspension For Injection (IM)
|
Prescription Drug (RX)
|
Type I pre-filled glass syringe x 1mL, with separate needle, packed in a blister (Box of 1's)
|
Vaccine
|
GlazoSmithKlineBiologicals SA
|
Belgium
|
|
GlaxoSmithKline Philippines, Inc.
|
|
Renewal
|
31 May 2024
|
14 August 2029
|
| View |
|
BR-1305
|
Filgrastim
|
None
|
300mcg/0.5mL
|
Solution for Injection (IV/SC)
|
Prescription Drug (RX)
|
1mL USP Type I Pre-filled syringe (Box of 2's)
|
-
|
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
|
China
|
|
SMHP Marketing & Consultancy
|
SMHP Marketing & Consultancy
|
-
|
05 March 2021
|
03 October 2024
|
| View |
BR-1306_PI_01.pdf
|
BR-1306
|
Quadrivalent Seasonal Influenza Vaccine (Split
Virion, Inactivated) Southern Hemisphere 2024 Strain
|
Vaxigrip Tetra
|
influenza strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
(A/California/122/2022, SAN-022)
15 μg of HA**
15 μg of HA*
***
15 μg of HA**
B/Austria/1359417/2021 (B/Victoria lineage)-like virus
(B/Michigan/01/2021, wild type)
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
(B/Phuket/3073/2013, wild type)
*Propagated in fertilized hen's eggs from healthy chicken flocks **Haemagglutinin
15 μg of HA**
|
Suspension for Injection (IM/SC)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL Type I pre-filled glass syringe with
chlorobutyl plunger stopper and needle (Box of 1's).
|
Vaccines
|
Sanofi Pasteur
|
France
|
|
Sanofi Pasteur, Inc.
|
Zuellig Pharma Corporation
|
Monitored Release (Strain Clearance)
|
19 February 2024
|
19 February 2025
|
| View |
|
BR-1307
|
Varicella Vaccine (Live, Attenuated)
|
Varilrix
|
Formulation:
After reconstitution, one dose (0.5 mL) contains not less than 103.3 plaque-forming units (PFU) live attenuated varicella-zoster virus (Oka Strain).
|
Lyophilized Powder For Injection (S.C.)
|
Prescription Drug (RX)
|
Type I colorless glass vial with bromobutyl rubber stopper and flip-off cap + 0.5 mL Type I pre-filled glass syringe (Water for Injection as diluent) with 2 separate needles (Box of 1's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
N/A
|
GlaxoSmithKline Philippines, Inc.
|
GlaxoSmithKline Philippines, Inc.
|
Initial (Variation)
|
25 July 2023
|
25 July 2028
|
| View |
|
BR-1308
|
Pneumococcal Conjugate Vaccine, 13-Valent
|
Prevenar 13
|
0.5 mL per dose
|
Suspension For Im Injection
|
Prescription Drug (RX)
|
2 mL pre-filled borosilicate glass vial (Type I) with chlorobutyl rubber stopper, aluminum seal and light blue flip off cap and vaccine vial monitor (box of 50's); Multi-dose (0.5 mL per dose)
|
-
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
|
Pfizer, Inc
|
Pfizer, Inc
|
Initial
|
12 December 2019
|
05 December 2024
|
| View |
|
BR-1309
|
Heparin Sodium
|
Heprin
|
1000IU/mL
|
Solution For Injection (Iv/Sc)
|
Prescription Drug (RX)
|
USP Type I Glass Vial with Green Flip-off Seal x 5 mL (Box of 10's and 25's)
|
Anticoagulant
|
Gland Pharma Limited
|
India
|
|
Endure Medical, Inc.
|
Endure Medical, Inc.
|
Renewal
|
31 May 2024
|
30 June 2029
|
| View |
|
BR-1310
|
Pneumococcal Polysaccharide And Non-Typeable Haemophilus Influenzae (Nthi) Protein D Conjugate Vaccine, Adsorbed
|
Synflorix
|
0.5mL
|
Suspension For Injection
|
Prescription Drug (RX)
|
2mL Suspension in a 3mL Type I Glass Vial with chlorobutyl rubber stopper and blue green flip-off cap with Vaccine Vial Monitor (VVM) (Box of 100's). Multidose.
|
-
|
Glaxosmithkline Biologicals
|
France
|
|
Glaxosmithkline Philippines, Inc.
|
Glaxosmithkline Philippines, Inc.
|
-
|
21 February 2020
|
22 February 2025
|
| View |
BR-1311_PI_01.pdf
|
BR-1311
|
Ustekinumab
|
Stelara
|
130mg/26mL
|
Concentrate for Solution For Infusion (Iv)
|
Prescription Drug (RX)
|
Type I glass Vial, crimped with aluminum seal with a light green flip-off button x 26mL (Box of 1's). Single Use Vial.
|
-
|
Cilag AG
|
Switzerland
|
|
Johnson & Johnson (Philippines), Inc.
|
|
-
|
02 April 2020
|
02 April 2025
|
| View |
BR-1313_PI_01.pdf
|
BR-1313
|
Erenumab
|
Aerinex
|
70 mg/mL
|
Solution For Injection (Sc)
|
Prescription Drug (RX)
|
1 mL Type I EP/USP prefilled glass Hypak SCF syringe barrel with grey bromobutyl elastomer plunger stopper and 27G x 1/2 inch staked needle with grey rubber needle shield enclosed in a rigid plastic cover in a plastic tray
|
-
|
Amgen Manufacturing Limited
|
United States of America
|
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Monitored Release
|
09 March 2020
|
09 March 2025
|
| View |
|
BR-1315
|
Pneumococcal Polysaccharide Vaccine, Polyvalent
|
Pneumovax 23
|
Each dose (0.5 mL) contains 25 mcg of each polysaccharide type (types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) dissolved in isotonic saline solution containing 0.25% phenol as a preservative.
|
Solution for Injection (I.M./ S.C.)
|
Prescription Drug (RX)
|
Type I Clear glass vial with rubber stopper enclosed in aluminum shell and pastic flip-off cap x 0.5mL (Box of 10's) (commercial and DOH use)
|
-
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
|
Merck Sharp & Dohme (I.A.) Corporation
|
|
-
|
02 April 2020
|
02 April 2025
|
| View |
|
BR-1316
|
Trastuzumab
|
Herzuma
|
150mg
|
Powder for Concentrate Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilacte glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap (Box of 1's)
|
-
|
Celltrion Inc, Republic of Korea
|
Korea
|
|
Celltrion Healthcare Philippines, Inc.
|
|
-
|
03 April 2020
|
03 April 2025
|
| View |
|
BR-1317
|
Trastuzumab
|
HERZUMA
|
440mg
|
Powder for Concentrate for Solution fro Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilacte glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap + Type I borosilicate glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap (20mL Bacteriostatic Water for Injection with 1.1% benzyl alcohol as diluent) (Box of 1's)
|
-
|
Celltrion Pharm, Inc.
|
Korea
|
|
Celltrion Healthcare Philippines, Inc.
|
|
-
|
03 April 2020
|
03 April 2025
|
| View |
BR-1318_PI_01.pdf
|
BR-1318
|
Follitropin Alfa / Lutropin Alfa
|
Pergoveris
|
350 IU/150 IU (0.48mL)
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
Multidose. 3mL EP/USP Type I pre-filled pen + 5 29G X 1/2" Double-ended needles in a box
|
-
|
Merck Serono S.p.A.
|
Italy
|
|
Merck, Inc.
|
Merck, Inc.
|
-
|
16 April 2020
|
16 April 2025
|